The MarginProbe® System is a new FDA-approved, real-time, tissue-assessment tool for early-stage breast-cancer surgery that is three times more effective than conventional methods.
In a conventional lumpectomy, excised tissue is sent to a pathology laboratory to be analyzed for cancer on the margins. It can take a week or more to receive these lab results, which typically yield an estimated 30 to 60 percent of patients needing to undergo further surgery.
Cancer cells, which contain more collagen than healthy cells, have a distinctive electromagnetic "signature." With the addition of MarginProbe,® doctors can quickly assess the electromagnetic properties of cells on the rim or edge of a suspected tumor during surgery.
This real-time information significantly improves surgeons' ability to identify "cancer on the margins" while a patient is still in the operating room, remove cancerous edges immediately and help eliminate the need for repeat procedures. And allows for quicker recovery and better peace of mind.